Antiviral Response of HCV Genotype 1 to Consensus Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin

Sjögren, Maria H.; Sjogren, Robert W.; Lyons, M.F.; Ryan, Michael J.; Santoro, John J.; Smith, Coleman I.; Reddy, K. Rajender; Bonkovsky, Herbert L.; Huntley, Brooke; Faris-Young, Sima

doi:10.1007/s10620-007-9757-9

Cited by 36 publications

(26 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results represent a three to sixfold improvement over the results achieved in prior non-responders utilizing a second course of peg-IFN [4][5][6][7][8][9] and confirm the results of others, who have used c-IFN [24][25][26][27][28][29][30][31][32]. The results are even more noteworthy in that 81% of the patients had a genotype 1 infection, 21% had cirrhosis, and 24% were African American at the initiation of their therapy, factors known to reduce response rates significantly.…”

Section: Discussionsupporting

confidence: 83%

Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin

2011

View full text Add to dashboard Cite

The use of c-IFN plus ribavirin in the retreatment of prior peg-IFN plus ribavirin partial responders is essentially twice that achieved in prior re-treatment regimens consisting of a second course of peg-IFN plus ribavirin. These results will need to be evaluated against the use of triple therapy consisting of a peg-IFN plus ribavirin and a protease inhibitor. More studies utilizing c-IFN plus ribavirin with either a protease inhibitor or polymerase inhibitor need to be performed as well.

show abstract

Section: Discussionsupporting

confidence: 83%

Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin

2011

View full text Add to dashboard Cite

show abstract

“…Initially, the rate of sustained viral response (SVR) was about 10% [28] . After ribavirin and pegylated-interferon became available, the rate of SVR reached 40-50% [29] . These interferon-based antiviral therapies have been shown to reduce the incidence of HCC in patients with SVR [30] .…”

mentioning

confidence: 99%

Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection

Ida¹,

Hagiwara²,

Kono³

et al. 2017

Dig Dis

View full text Add to dashboard Cite

Background: Interferon-based antiviral therapies against hepatitis C virus (HCV) infection have been shown to reduce the incidence of hepatocellular carcinoma (HCC) in patients with sustained viral response (SVR). Recently, direct-acting antivirals (DAAs) have been proven to be much more effective in achieving SVR than interferon-based therapies. However, whether DAAs can efficiently prevent the occurrence of HCC after SVR remains controversial. To clarify this issue, we analyzed the clinical features of patients in whom HCC developed after achievement of SVR with DAAs for chronic HCV infection. Summary: Among patients who achieved SVR with daclatasvir and asunaprevir (n = 100), HCC developed in 17 patients (HCC group; n = 17) and did not develop in 83 patients (non-HCC group; n = 83) during a mean observation period of 15 months. A multivariate Cox proportional hazards analysis identified past history of HCC and male sex as significant risk factors for the emergence of HCC after DAAs. Sixteen cases with HCC after DAAs were in the very early or early stage (16/17, 94.1%), and one case was in the advanced stage (1/17, 5.9%) with portal venous tumor thrombus. Radiofrequency ablation and/or transarterial chemoembolization were performed in most cases as curative therapy (16/17, 94.1%). Key Messages: SVR by DAAs did not completely prevent the occurrence of HCC. However, even if HCC did develop after SVR, curative anticancer therapy was applicable in most cases.

show abstract

“…Although one recent study revealed that CIFN 3 times weekly in combination with weight-based RBV may be as effective as combination PEG IFN alfa-2b and weight-based RBV in the treatment of HCV genotype 1 patients, comparative data are limited. 32 Therefore CIFN is not considered the standard of care for naïve patients with chronic HCV infection.…”

Section: Consensus Interferon In Naïve Patients With Chronic Hepatitis Cmentioning

confidence: 99%

Management of chronic hepatitis C treatment failures: role of consensus interferon

Gonzalez¹,

Keeffe²

2009

BTT

View full text Add to dashboard Cite

A signifi cant proportion of patients with chronic hepatitis C virus (HCV) infection who undergo antiviral therapy have persistent or recurrent viremia and fail to achieve a sustained virologic response (SVR). Factors associated with treatment failure include HCV genotype 1 infection, high serum HCV RNA levels, and advanced fi brosis. Consensus interferon (CIFN) is a synthetic type I interferon derived from a consensus sequence of the most common amino acids found in naturally occurring alpha interferon subtypes. Several prospective clinical studies have demonstrated that CIFN may be a treatment option in patients who have failed prior interferonbased therapy, including those who have failed combination therapy with standard interferon or peginterferon plus ribavirin. Daily CIFN in combination with ribavirin may be an effective regimen in this setting; however, optimal dose and treatment duration of CIFN therapy have not been well established. Patients who achieve viral suppression during prior interferon-based therapy and those who do not have advanced fi brosis have a greater likelihood of achieving a SVR with CIFN retreatment. Individualized therapy targeting specifi c patient groups will be an important consideration in the successful management of prior treatment failures. Additional prospective studies are required in order to identify optimal treatment strategies for the use of CIFN in these patients.

show abstract

Antiviral Response of HCV Genotype 1 to Consensus Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin

Cited by 36 publications

References 29 publications

Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin

Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin

Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection

Management of chronic hepatitis C treatment failures: role of consensus interferon

Contact Info

Product

Resources

About